{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:03:55Z","timestamp":1777136635162,"version":"3.51.4"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Modification of pathogenic antibodies for autoimmune diseases illuminated the biologic relevance of B cells, plasma cells, and pathogenic antibodies in autoimmunity. They have also rejuvenated interest in how B cells mediate multiple effector functions that include antibody production, antigen presentation to T cells, costimulation, and the production of immune stimulating and immune modulatory cytokines. Repurposing these drugs from autoimmunity and cancer immunotherapy has yielded important advancements in the care of antibody-mediated rejection patients and novel drug development aimed at HLA desensitization have recently emerged. We now stand on an important threshold that promises many advances in the care of our allosensitized patients. We hope that these initial advances will encourage basic scientist, clinical investigators, industry, National Institutes of Health, our academic societies, and the Food and Drug Administration to continue support of these important objectives. These advances clearly have implications for sensitized patients receiving solid organ transplants and antibody-mediated rejection treatment. Modification of alloimmunity and alloantibodies will also have relevance to xenotransplantation where the xenoantibodies present a formidable obstacle to advancement of this important therapy. Working together, we can advance transplant therapeutics where biologic agents are likely to play novel and important roles. Here, we discuss novel drugs emerging in this area.<\/jats:p>","DOI":"10.1097\/tp.0000000000002462","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T07:06:42Z","timestamp":1538204802000},"page":"262-272","source":"Crossref","is-referenced-by-count":33,"title":["Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection"],"prefix":"10.1097","volume":"103","author":[{"given":"Stanley C.","family":"Jordan","sequence":"first","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Ammerman","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jua","family":"Choi","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Huang","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Peng","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supreet","family":"Sethi","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiad","family":"Najjar","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieko","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathlyn","family":"Lim","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Louie","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Vo","sequence":"additional","affiliation":[{"name":"Comprehensive Transplant Center, Transplant Immunotherapy Program, Cedars-Sinai Medical Center, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20231002","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.4049\/jimmunol.1401190","article-title":"Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production","volume":"194","year":"2015","journal-title":"J Immunol"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1681\/ASN.2007010073","article-title":"Antibody-mediated renal allograft rejection: diagnosis and pathogenesis","volume":"18","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","year":"2014","journal-title":"Am J Transplant"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"bib5-20231002","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.08140910","article-title":"Desensitization protocols and their outcome","volume":"6","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"bib7-20231002","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib8-20231002","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/TP.0b013e3182802f88","article-title":"Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab","volume":"95","year":"2013","journal-title":"Transplantation"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrneph.2012.81","article-title":"The impact of donor-specific anti-HLA antibodies on late kidney allograft failure","volume":"8","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":"Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')","volume":"7","year":"2007","journal-title":"Am J Transplant"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/j.1600-6143.2008.02262.x","article-title":"The spectrum of antibody-mediated renal allograft injury: implications for treatment","volume":"8","year":"2008","journal-title":"Am J Transplant"},{"key":"bib13-20231002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(12)61265-3","article-title":"Antibody-mediated vascular rejection of kidney allografts: a population-based study","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"bib14-20231002","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00467-009-1386-4","article-title":"Advances in diagnosing and managing antibody-mediated rejection","volume":"25","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"bib15-20231002","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","year":"2014","journal-title":"Am J Transplant"},{"key":"bib16-20231002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","year":"2018","journal-title":"Am J Transplant"},{"key":"bib17-20231002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.humimm.2016.01.018","article-title":"Current outcomes of chronic active antibody mediated rejection - a large single center retrospective review using the updated BANFF 2013 criteria","volume":"77","year":"2016","journal-title":"Hum Immunol"},{"key":"bib18-20231002","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent\/recurrent versus de novo donor-specific antibodies","volume":"91","year":"2017","journal-title":"Kidney Int"},{"key":"bib20-20231002","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1681\/ASN.2016070797","article-title":"Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients","volume":"28","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"bib21-20231002","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1681\/ASN.2017040367","article-title":"Targeting B cells and plasma cells in glomerular diseases: translational perspectives","volume":"29","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"bib22-20231002","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ajt.13052","article-title":"Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"bib23-20231002","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/TP.0000000000000064","article-title":"Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients","volume":"98","year":"2014","journal-title":"Transplantation"},{"key":"bib24-20231002","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/TP.0b013e31827be3c1","article-title":"Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA","volume":"95","year":"2013","journal-title":"Transplantation"},{"key":"bib25-20231002","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1600-6143.2011.03830.x","article-title":"Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"bib26-20231002","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial","volume":"18","year":"2018","journal-title":"Am J Transplant"},{"key":"bib27-20231002","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs","volume":"170","year":"2003","journal-title":"J Immunol"},{"key":"bib28-20231002","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"bib29-20231002","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"bib32-20231002","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.14504","article-title":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","volume":"18","year":"2018","journal-title":"Am J Transplant"},{"key":"bib33-20231002","first-page":"2600","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib34-20231002","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.4049\/jimmunol.1500940","article-title":"Cutting edge: CTLA-4Ig inhibits memory B cell responses and promotes allograft survival in sensitized recipients","volume":"195","year":"2015","journal-title":"J Immunol"},{"key":"bib35-20231002","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trim.2016.08.001","article-title":"Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization","volume":"38","year":"2016","journal-title":"Transpl Immunol"},{"key":"bib36-20231002","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2017060679","article-title":"Control of Humoral response in renal transplantation by Belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk","volume":"29","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"bib37-20231002","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nm.3245","article-title":"Cancer's true breakthroughs","volume":"19","year":"2013","journal-title":"Nat Med"},{"key":"bib38-20231002","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","year":"2011","journal-title":"J Immunol"},{"key":"bib40-20231002","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"bib41-20231002","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/TP.0000000000001330","article-title":"32 Doses of bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody","volume":"101","year":"2017","journal-title":"Transplantation"},{"key":"bib42-20231002","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.14222","article-title":"Proteasome inhibitor carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings","volume":"17","year":"2017","journal-title":"Am J Transplant"},{"key":"bib43-20231002","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2017010991","article-title":"Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates","volume":"1","year":"2017","journal-title":"Blood Adv"},{"key":"bib44-20231002","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review","volume":"151","year":"2018","journal-title":"Eur J Med Chem"},{"key":"bib45-20231002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib46-20231002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/2040620716654102","article-title":"Ibrutinib in Waldenstr\u00f6m macroglobulinemia: latest evidence and clinical experience","volume":"7","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"bib50-20231002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.trim.2017.09.003","article-title":"Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization","volume":"45","year":"2017","journal-title":"Transpl Immunol"},{"key":"bib51-20231002","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","year":"2015","journal-title":"Nat Immunol"},{"key":"bib52-20231002","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000255","article-title":"The biology behind interleukin-6 targeted interventions","volume":"28","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"bib53-20231002","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"bib54-20231002","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3227","article-title":"Regulatory immune cells in transplantation","volume":"12","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"bib59-20231002","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","article-title":"A phase I\/II trial of the Interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients","volume":"99","year":"2015","journal-title":"Transplantation"},{"key":"bib60-20231002","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","year":"2017","journal-title":"Am J Transplant"},{"key":"bib61-20231002","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","article-title":"The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo\/active-controlled, dose-ranging study","volume":"67","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"bib62-20231002","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","year":"2015","journal-title":"Transplantation"},{"key":"bib63-20231002","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/TP.0000000000000995","article-title":"Potential roles for C1 inhibitor in transplantation","volume":"100","year":"2016","journal-title":"Transplantation"},{"key":"bib64-20231002","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"bib65-20231002","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"bib66-20231002","first-page":"3197042","article-title":"Eculizumab for thrombotic microangiopathy associated with antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"2017","year":"2017","journal-title":"Case Rep Transplant"},{"key":"bib67-20231002","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"bib68-20231002","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.transproceed.2013.02.062","article-title":"Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports","volume":"45","year":"2013","journal-title":"Transplant Proc"},{"key":"bib69-20231002","first-page":"E1","article-title":"Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody","volume":"18","year":"2014","journal-title":"Pediatr Transplant"},{"key":"bib70-20231002","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"bib71-20231002","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment","volume":"29","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"bib72-20231002","article-title":"Novel approaches to block complement","year":"2018","journal-title":"Transplantation"},{"key":"bib73-20231002","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial","volume":"18","year":"2018","journal-title":"Am J Transplant"},{"key":"bib75-20231002","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG Endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib76-20231002","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","article-title":"IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G","volume":"21","year":"2002","journal-title":"EMBO J"},{"key":"bib77-20231002","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.113.086470","article-title":"Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase","volume":"83","year":"2013","journal-title":"Mol Pharmacol"},{"key":"bib79-20231002","first-page":"5672523","article-title":"Impact of desensitization on antiviral immunity in HLA-sensitized kidney transplant recipients","volume":"2017","year":"2017","journal-title":"J Immunol Res"},{"key":"bib80-20231002","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1529-8027.2011.00328.x","article-title":"An open label clinical trial of complement inhibition in multifocal motor neuropathy","volume":"16","year":"2011","journal-title":"J Peripher Nerv Syst"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007890-201902000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:03:41Z","timestamp":1696223021000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201902000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002462","relation":{},"ISSN":["1534-6080","0041-1337"],"issn-type":[{"value":"1534-6080","type":"electronic"},{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}